The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the BioVaxys Technology Corp stock forecast from 0 analysts, the average analyst target price for BioVaxys Technology Corp is not available over the next 12 months. BioVaxys Technology Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioVaxys Technology Corp is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, BioVaxys Technology Corp’s stock price was CAD 0.075. BioVaxys Technology Corp’s stock price has changed by +36.36% over the past week, +7.14% over the past month and +275.00% over the last year.
No recent analyst target price found for BioVaxys Technology Corp
No recent average analyst rating found for BioVaxys Technology Corp
Company Overview BioVaxys Technology Corp
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada. Address: 146 Thirtieth Street, Etobicoke, ON, Canada, M8W 3C4 Read Less
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating can...Read More
N/A
N/A
0
N/A
CAD
Canada
Adjusted Closing Price for BioVaxys Technology Corp (BIOV:CA)
Loading...
Unadjusted Closing Price for BioVaxys Technology Corp (BIOV:CA)
Loading...
Share Trading Volume for BioVaxys Technology Corp Shares
Loading...
Compare Performance of BioVaxys Technology Corp Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for BIOV:CA
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To BioVaxys Technology Corp (Sector: Biotechnology )
Frequently Asked Questions About BioVaxys Technology Corp (BIOV:CA) Stock
Stock Target Advisor's fundamental analysis for BioVaxys Technology Corp's stock is Bearish.
Unfortunately we do not have enough data on BIOV:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BIOV:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BIOV:CA's stock to indicate if its overvalued.
The last closing price of BIOV:CA's stock was CAD 0.08.
The most recent market capitalization for BIOV:CA is CAD 0.02B.
Unfortunately we do not have enough analyst data on BIOV:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BioVaxys Technology Corp's stock.
As per our most recent records BioVaxys Technology Corp has 0 Employees.
Sorry we do not have any infomation available on BioVaxys Technology Corp's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIOV:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
